Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias

计划入组 16 人 · 首次发布于 2011 年 7 月 18 日

Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer

计划入组 38 人 · 首次发布于 2015 年 7 月 23 日

Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia

计划入组 5 人 · 首次发布于 2015 年 5 月 8 日

BVD-PI3K gamma

IHMT-PI3K-455

PI3K inhibitor (cancer)

Exelixis, Inc.

United States

Inhibikase Therapeutics

United States

Regeneron Pharmaceuticals

United States

NGS and Targeted Therapies Improve Survival in HR+/HER2- Breast Cancer

PADMA Trial: Palbociclib Plus Endocrine Therapy Significantly Extends Time to Treatment Failure in Advanced Breast Cancer

Adlai Nortye's Buparlisib Poised to Potentially Be First PI3K Inhibitor for Head and Neck Cancer